Open Access

Predictors of switching from beta-blockers to other anti-hypertensive drugs: a review of records of 19,177 Chinese patients seen in public primary care clinics in the New Territory East, Hong Kong

  • Martin CS Wong1,
  • Harry HX Wang1,
  • Johnny Y Jiang2Email author,
  • Stephen Leeder3 and
  • Sian M Griffiths1
Asia Pacific Family Medicine201110:10

DOI: 10.1186/1447-056X-10-10

Received: 19 April 2011

Accepted: 27 July 2011

Published: 27 July 2011

Abstract

Background

Beta-blocker drugs are commonly used in family practice and studies showed that they were the most popularly prescribed medications among all antihypertensive agents. This study aimed to identify the factors associated with medication switching from a beta-blocker to another antihypertensive drug among Chinese patients.

Methods

We used a validated database which consisted of the demographic and clinical information of all Chinese patients prescribed a beta-blocker from any public, family practice clinics between 01 Jan 2004 to 30 June 2007 in one large Territory of Hong Kong. The proportion of patients switched from beta-blockers to another antihypertensive agent 180 days within their first prescription was studied, and the factors associated with medication switching were evaluated by using multivariate regression analyses.

Results

From 19,177 eligible subjects with a mean age of 59.1 years, 763 (4.0%) were switched from their beta-blockers within 180 days of commencing therapy. A binary logistic regression model used medication switching as the outcome variable and controlled for age, gender, socioeconomic status, clinic setting (general out-patient clinics, family medicine specialist clinic or staff clinics), district of residence, visit type (new vs. follow-up attendance), the number of concomitant co-morbidities, and the calendar year of prescription. It was found that older patients (age 50-59 years: adjusted odds ratio [AOR] 1.38, 95% C.I. 1.12-1.70; p = 0.002; age 60-69 years: AOR 1.63 95% C.I. 1.30-2.04, p < 0.001; age ≥ 70 years: AOR 1.82, 95% C.I. 1.46-2.26, p < 0.001; referent age < 50 years) and new visitors (AOR 0.57, 95% C.I. 0.48-0.68, p < 0.001) were more likely to have their medication switched.

Conclusions

Closer monitoring of the medication taking behavior among the older patients and the new clinic visitors prescribed a beta-blocker is warranted. Future studies should evaluate the reasons of drug switching.

Keywords

beta-blocker switching pharmacoepidemiology family practice

Background

Hypertension is a global health problem and represents one of the most important, modifiable risk factors for renal and cardiovascular diseases [1] It affects more than 30% of the general US population [2], and estimates of the cost of the disorder are around $66.4 billion worldwide in 2007 [3]. Its prevalence is high over the globe, including Asia Pacific countries [4]. Despite the effectiveness of antihypertensive pharmacotherapy to mitigate its complications [5, 6], the control of hypertension remained suboptimal [7]. In family practice, its total yearly costs were approximately £76.5 million, of which £26.9 million was attributed to patients who discontinue or switch their pharmacotherapy [8].

Beta-blockers are commonly used in family practice to manage a wide variety of chronic diseases, including hypertension. Together with calcium channel blockers, beta-blockers are one of the most commonly prescribed antihypertensive agents in primary care settings [9]. The clinical guidelines used in the clinics of the public sector in Hong Kong were mainly from the 7th Joint National Committee Seventh Report. Therefore, the major antihypertensive drug classes were regarded as equally acceptable as first-line prescriptions for management of arterial hypertension since 2003 [10]. In our recent studies on switching of antihypertensive drug therapies in Hong Kong, we found that among more than 93,000 subjects with hypertension, 5.7% switched their medications to another antihypertensive drug class within 180 days of their prescriptions [11]. Subjects at higher risks of medication switching were evaluated, and the risk factors included young age, female gender, attendance in family medicine clinics, new visitors and those prescribed thiazide diuretics as well [11]. However when we conducted stratified analysis of each antihypertensive drug class in the same group of patients, the associated factors of medication switching were different which signified a drug-class specific heterogeneity [12, 13]. Beta-blocker is a distinct group of antihypertensive agent which has different efficacy depending on demographic groups and other comorbid conditions [14].

Previous studies among Caucasian populations have identified the risk factors associated with antihypertensive drug switching [1519]. Nevertheless, ethnicity might be a factor which limits the generalizability of these findings, since patients in the Asia Pacific region might have a different profile of medication switching due to different pharmacological actions of beta-blockers [20, 21]. In particular, studies on patients of Chinese ethnicity are particularly scarce despite the fact that they constitute one-fifth of the world's population. Chinese patients were shown to be more sensitive to beta-blockade effect when compared to white patients [22].

The primary objective of this study is to identify the independent factors associated with switching of beta-blockers in family practice. We tested the association between age, gender, socioeconomic status, service setting (general out-patient clinic [GOPC] or family medicine specialist clinic [FMSC] or staff clinic), district of residence, visit type (initial or follow-up visits) and the number of co-morbidities, which were also the variables tested in our previous studies [1113].

Methods

Data Source

A detailed methodology has been presented elsewhere [9, 11, 23]. The Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority (HA) of Hong Kong consists of 7 million patient records, 1 million annual admissions and 13 million ambulatory visits, with research as one of its objectives [24]. The computerized system consists of patients' demographic and clinical information, medical diagnoses in the forms of International Classification of Primary Care version 2 (ICPC-2) codes, types of clinical services (location) and details on medication prescriptions. This database has previously been investigated and the demographic (100%) and prescription details were 99.98%) complete [9].

When patients visit public primary care clinics in Hong Kong, they register with their identity documents. Socio-demographic information is recorded by the reception staff, and entered into the computer system as are drug prescription (with paper script back-up during computer down-times) for both public and private systems.. All drug items were checked by two qualified dispensers or pharmacists. Records are unified so that they are available at any primary care clinics where the patient presents. Clinical guidelines assist physicians to enter the clinical diagnoses for each consultation using ICPC-2 codes.

This study retrieved patient information from the New Territory East cluster (NTE) of Hong Kong, which offers primary healthcare services to approximately 1.3 million residents, or 17.2% of the Hong Kong population [25]. The territory is further divided into three geographical regions, namely Shatin (urbanized), Taipo and North districts (rural). The median monthly household incomes of residents in these three regions in 2006 were US$2,510, US$2,338 and US$2,078, respectively, which were comparable to the Hong Kong-wide figure of US$2,240 [25]. The median ages in these three regions were similar (38-39 years: median age of 39 years for Hong Kong). We obtained ethical approval from the Survey and Behavioural Research Ethics Committee of the Chinese University of Hong Kong. All patients were anonymized and their identities were replaced by unique identifiers, hence informed consent was not required.

Definition of the cohort

All adult patients aged ≥ 18 years who attended a primary care clinic in the NTE region during the study period January, 2004 to June, 2007, for whom at least one antihypertensive medication was prescribed, were included in our analysis. Each patient was assigned the number of co-morbidities according to the number of concomitant cardiovascular disorders other than ICPC-2 K86 [uncomplicated hypertension] (e.g., diabetes mellitus, cerebrovascular diseases, lipid disorders) and medical conditions which could potentially influence prescription of a particular class of antihypertensive drug (e.g., gout, asthma, ischemic heart diseases, benign prostatic hypertrophy). Table 1 shows a complete list of these medical conditions with their respective ICPC-2 codes.
Table 1

Comorbidities according to the respective International Classification of Primary Care (ICPC) Codes

ICPC codes

Disease entity

T90

Diabetes Mellitus

T901

Impaired glucose tolerance

T92

Gout

T93

Lipid disorders

K90

Stroke/cerebrovascular accident

K91

Cerebrovascular disease

K74

Ischemic Heart Disease with angina

K76

Ischemic Heart Disease without angina

K75

Acute Myocardial Infarction

K77

Heart Failure

K84

Heart Disease, other

K99

Cardiovascular disease, other

R79

Chronic Bronchitis

R95

Chronic Obstructive Pulmonary Disease

R96

Asthma

U14

Kidney symptoms/complaints

U88

Glomerulonephritis/nephrosis

Y85

Benign Prostatic Hypertrophy

U78

Benign Neoplasm Urinary Tract

Y79

Benign/unspecified neoplasm, male genital

Exposure to drugs and assessment of switching

The rate of medication switching within 180 days of their prescription was computed. We defined drug switching as "the absence of a refill prescription in all subsequent clinic visits with issuance of another antihypertensive drug of a different antihypertensive drug class within the time frame of 180 days since the first prescription date" [11]. A time frame of 180 days was used instead of 90 days since the durations of antihypertensive prescriptions were variable, ranging from 14 to 168 days (median 56 days).

Covariates and statistical analysis

We used the same variables in a previous study [11] to test for associations with the primary outcome, namely medication switching 180 days within their prescriptions. The covariates included age, gender, socioeconomic status in terms of fee-payers vs. fee-waivers, service type, district of residence, visit type, the number of comorbidities and the calendar years of prescriptions. Fee waivers are mainly subjects receiving social security allowances from the government. To apply for fee waiving, applicants will receive a comprehensive assessment by a professional in the social welfare sector in order to certify their inability to pay for clinical consultation fees. Each consultation charges US$5.77, including investigation and medication fees. We defined new visitors as patients who have never been prescribed any antihypertensive medications in any clinics under HA. One unconditional, binary logistic regression analysis was conducted of all eligible patients, and all the predictor variables were entered into the regression models. The Statistical Package for Social Sciences version 15.0 (SPSS Incorporation, Chicago Illinois) was used for all data analysis. All p values ≤ 0.05 were regarded as statistically significant.

Results

A total of 19,177 eligible patients were included in the present study. 41.5% were aged ≥ 60 years, and the majority were female (62.8%) (Table 2). Most were fee-payers (73.5%), attended GOPCs for the consultations (90.2%), lived in more urbanized regions (Shatin and Taipo: 70.8%), and were first-ever visitors (61.6%). Among them, 83.2% had no co-morbidities, and most prescriptions were issued in the calendar years 2004 (51.2%) and 2005 (22.7%).
Table 2

Patient characteristics (N = 19,177)

 

No.

%

Age (years)

  

< 50

5,327

27.8

50-59

5,885

30.7

60-69

3,863

20.1

≥ 70

4,102

21.4

Gender

  

Male

7,133

37.2

Female

12,044

62.8

Payment status

  

Fee waivers

5,088

26.5

Fee payers

14,089

73.5

Service type

  

GOPC

17,294

90.2

FMSC

1,704

8.9

Staff clinic

179

0.9

District of residence

  

Shatin

8,905

46.4

Taipo

4,684

24.4

North

4,246

22.1

Others

1,342

7.0

Visit type

  

New

11,817

61.6

Old

7,360

38.4

Comorbidities

  

0

15,952

83.2

1

2,774

14.5

2

432

2.3

> 3

19

0.1

Calendar years of prescription

  

2004

9,826

51.2

2005

4,360

22.7

2006

3,402

17.7

2007

1,589

8.3

GOPC: General Out-patient Clinic; FMSC: Family Medicine Specialist Clinic; CCB: Calcium Channel Blockers; All the percentages are across columns

Table 3 shows the characteristics of patients who switched compared with those who continued their beta-blocker prescriptions. A total of 4.0% switched their medication within 180 days. When compared with drug continuers, those who switched their prescriptions were older, more were female (64.0% vs. 62.8%), fee payers (73.9% vs. 73.4%), and visitors of GOPCs (91.9% vs. 90.1%) (all p < 0.001). In addition, more patients who switched lived in more rural districts (the North region; 24.4% vs. 22.0%), were new visitors (74.7% vs. 61.1%) and had more co-morbidities (17.3% vs. 16.7%) (all p < 0.001).
Table 3

Characteristics of beta-blockers switchers and non-switchers (N = 19,177)

 

Switchers

(n = 763)

non-switchers (n = 18,414)

p

 

No.

%

No.

%

 

Age (years)

     

< 50

158

20.7

5,169

28.1

< 0.001

50-59

229

30.0

5,656

30.7

 

60-69

171

22.4

3,692

20.0

 

≥ 70

205

26.9

3,897

21.2

 

Gender

     

Male

275

36.0

6,858

37.2

< 0.001

Female

488

64.0

11,556

62.8

 

Payment status

     

Fee waivers

199

26.1

4,889

26.6

< 0.001

Fee payers

564

73.9

13,525

73.4

 

Service type

     

GOPC

701

91.9

16,593

90.1

< 0.001

FMSC

59

7.7

1,645

8.9

 

Staff clinic

3

0.4

176

1.0

 

District of residence

     

Shatin

357

46.8

8,548

46.4

< 0.001

Taipo

177

23.2

4,507

24.5

 

North

186

24.4

4,060

22.0

 

Others

43

5.6

1,299

7.1

 

Visit type

     

New

570

74.7

11,247

61.1

< 0.001

Old

193

25.3

7,167

38.9

 

Comorbidities

     

0

630

82.6

15,322

83.2

< 0.001

1

114

14.9

2,660

14.4

 

≥ 2

19

2.5

432

2.3

 

Calendar years of prescription

     

2004

279

36.6

9,547

51.8

< 0.001

2005

227

29.8

4,133

22.4

 

2006

189

24.8

3,213

17.4

 

2007

68

8.9

1,521

8.3

 

GOPC: General Out-patient Clinic; FMSC: Family Medicine Specialist Clinic. All the percentages were across columns.

From a binary logistic regression model, patients who were older (≥ 50 years; adjusted odds ratio [AOR] ranged from 1.38 to 1.82) and new clinic visitors (AOR for follow-up visitors = 0.57, 95% C.I. 0.48 to 0.68, p < 0.001) were significantly more likely to have their medication switched (Table 4). There were no statistically significant associations detected between other covariates with the outcome variable. When we used 240 days and 360 days as the yardsticks of medication switching and re-conducted the regression analyses, similar significant associations were detected for age and visit type. There existed no multi-colinearity for the regression models, suggesting their statistical robustness.
Table 4

Factors associated with switching of beta-blockers (N = 19,177, r2 = 0

 

No.

%

Adjusted odds ratios

(95% C.I.)

p

Age

    

< 50

158

3.0

1.00 (reference)

 

50-59

229

3.9

1.38 (1.12-1.70)

0.002

60-69

171

4.4

1.63 (1.30-2.04)

< 0.001

≥ 70

205

5.0

1.82 (1.46-2.26)

< 0.001

Gender

    

Female

275

2.3

1.00 (reference)

 

Male

488

6.8

0.89 (0.76-1.03)

0.125

Payment status

    

Fee waivers

199

3.9

1.00 (reference)

 

Fee payers

564

4.0

1.02 (0.87-1.21)

0.792

Service type

    

GOPC

701

4.1

1.00 (reference)

 

FMSC

59

3.5

0.97 (0.73-1.28)

0.817

Staff clinic

3

1.7

0.47 (0.15-1.48)

0.196

District of residence

    

Shatin

357

4.0

1.00 (reference)

 

Taipo

177

3.8

0.95 (0.79-1.15)

0.606

North

186

4.4

1.07 (0.88-1.29)

0.505

Others

43

3.2

0.82 (0.59-1.13)

0.223

Visit type

    

New

570

4.8

1.00 (reference)

 

Old

193

2.6

0.57 (0.48-0.68)

< 0.001

Comorbidities

    

0

630

3.9

1.00 (reference)

 

1

114

4.1

1.17 (0.95-1.45)

0.150

≥ 2

19

4.2

1.23 (0.76-2.00)

0.396

GOPC: General Out-patient Clinic; FMSC: Family Medicine Specialist Clinic; CCB: Calcium Channel Blockers; RAS: Drugs acting on the rennin-angiotensin system. %: represents the percentages of patients with drugs discontinued.

Discussion

From this retrospective cohort consisting of 19,177 Chinese patients, we reported that older age and first clinic visits were significant predictors of medication switching. The other factors previously shown to be associated with antihypertensive drug switching [11], including gender, service type, district of residence, visit type and co-morbidities, were no longer statistical significant. Thus far there were no studies of this scale which evaluated the factors associated with switching from a beta-blocker to another antihypertensive prescription.

The mechanism where beta-blockers lower blood pressure could be multifactorial [26]. Some suggested mechanisms included diminution of sympathetic outflow mediated by the effect of the central nervous system, and reduced cardiac output accompanied by increased peripheral resistance [27]. Among the elderly, hypertension is characterized by compromised cardiac output and escalated peripheral vascular resistance [28, 29]. Beta-blockers used in the long term may lead to homeostatic adjustments that can improve cardiac output but will then be depressed when compared with the original state. Furthermore, there has been evidence that lipophilic beta-blockers can easily cross the blood-brain barrier, which induces more depression, sedation and sexual dysfunction in older subjects [30]. In addition, beta-blockers have strong potentials to induce conduction abnormalities, undesirable bradycardia, and development of heart failure especially among elderly with left ventricular dysfunction [3032].

Evidence points towards the relative ineffectiveness of beta-blockers as a treatment regimen for hypertension among the elderly populations. For instance, one meta-analysis including more than 16,000 elderly subjects 60 years or older reported that beta-blockers were incapable to prevent coronary heart diseases, fatal or non-fatal myocardial infarctions [33]. Also, when compared with other antihypertensive therapies, beta-blockers were the least effective in reducing left ventricular mass in the elderly although the effects on blood pressure lowering were similar across major antihypertensive drug classes [3436]. Therefore with an exception of the Joint National Committee 7th report, beta-blocker has not been recommended as a first-line agent in the elderly without any concomitant disorders like congestive heart failure or myocardial infarction [37].

Medication switching is essentially a physician-initiated action, but the patient could have influence. The physician might perceive the initial beta-blocker regimen is better replaced by a more efficacious antihypertensive medication to control blood pressure or other cardiovascular risk factors. For instance, elderly patients are more likely to suffer from poorly controlled diabetes and impaired glucose tolerance, and switching of beta-blockers to another agent is warranted. It can also be patient-driven, like a complaint of intolerable adverse events. Our findings that older subjects were more likely to have their beta-blockers switched could be explained by either or both of the above reasons. That the new visitors were more likely to have their medication switched is not surprising, as the follow-up patients might already have refilled their medications for at least once and should be arguably free of adverse effects when compared with the new clinic attendees.

Our study included a large number of Chinese subjects. The good dispensing practice in the primary care out-patient clinics allowed an accurate analysis of prescription patterns free of recall biases. However some limitations should be mentioned. Firstly this study included a Chinese population from only one geographical region out of seven in Hong Kong, although the demographic features of our samples are similar to all residents in Hong Kong. In addition, we captured only short-term switching profiles, and longer term prescription changes could not be assessed. Furthermore, the reasons of medication switching could not be evaluated from retrospective database analyses, and there remained some confounding factors like blood pressure level, body mass index, lifestyle habits and attitudes towards taking of chronic medications which could not be controlled for.

Conclusions

The implication of this study is that more careful practice of prescribing beta-blockers is needed particularly among the elderly and also the new visitors, who are more likely to be drug-naive. Translated into clinical practice, family physicians should attempt closer monitoring of the medication taking behavior of their patients with these risk factors. In the broader context of primary care, a multidisciplinary team of healthcare professionals should collaborate and strengthen medication management in the community. This could involve community pharmacists who can give timely advice to patients regarding medication counseling and support.

The future direction of research should be targeted towards the reasons of medication switching, and to what degree family physicians were influenced by evidence-based guidelines regarding prescription of first-line antihypertensive agents.

Authors' information

not applicable

List of abbreviations

AOR: 

adjusted odds ratios

CDARS: 

Clinical Data Analysis and Reporting System

FMSC: 

Family Medicine Specialist Clinic

GOPC: 

General Out-Patient Clinic

HA: 

Hospital Authority

ICPC-2: 

International Classification of Primary Care, version 2

NTE: 

New Territory East

Declarations

Acknowledgements

The authors would like to thank the Hospital Authority and the primary care research group of the School of Public Health, Chinese University of Hong Kong for their expert input. The abstract of this paper has been presented in the 18th WONCA Regional Conference for Asia Pacific and won the third prize in the WONCA Asia Pacific and Chinese Taipei Association Research Contest, Oral Category, held in Cebu in February 2011.

Authors’ Affiliations

(1)
School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong; HKSAR
(2)
Chinese Academy of Medical Science & Peking Union Medical College
(3)
Menzies Centre for Health Policy, School of Public Health, The University of Sydney

References

  1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ: Selected major risk factors and global and regional burden of disease. Lancet 2002, 360: 1347–1360. 10.1016/S0140-6736(02)11403-6PubMedView ArticleGoogle Scholar
  2. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007, 49: 69–75.PubMedView ArticleGoogle Scholar
  3. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113: e85–151. 10.1161/CIRCULATIONAHA.105.171600PubMedView ArticleGoogle Scholar
  4. Morgan T: Hypertension in the Asian Pacific region: the problem and the solution. J Hypertens 2008, 26: 1883–5. 10.1097/HJH.0b013e32830a976ePubMedView ArticleGoogle Scholar
  5. Wang TJ, Stafford RS: National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 1998, 158: 1901–1906. 10.1001/archinte.158.17.1901PubMedView ArticleGoogle Scholar
  6. Klungel OH, Heckbert SR, Longstreth WT Jr, Furberg CD, Kaplan RC, Smith NL, Lemaitre RN, Leufkens HG, de Boer A, Psaty BM: Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med 2001, 161: 37–43. 10.1001/archinte.161.1.37PubMedView ArticleGoogle Scholar
  7. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M: Hypertension Treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43: 10–17. 10.1161/01.HYP.0000116289.91160.73PubMedView ArticleGoogle Scholar
  8. Hughes D, McGuire A: The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998, (12):533–7.Google Scholar
  9. Wong MCS, Jiang JY, Tang JL, Lam A, Fung H, Mercer SW: Health services research in the public healthcare system in Hong Kong: An analysis of over 1 million antihypertensive prescriptions between 2004–2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. BMC Health Services Research 2008, 8: 138. 10.1186/1472-6963-8-138PubMed CentralPubMedView ArticleGoogle Scholar
  10. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289: 2560–72. 10.1001/jama.289.19.2560PubMedView ArticleGoogle Scholar
  11. Wong MCS, Jiang Y, Griffiths S: Switching of antihypertensive drugs among 93,286 Chinese patients: a cohort study. Journal of Human Hypertension 2010.Google Scholar
  12. Wong MCS, Jiang JY, Griffiths SM: Factors associated with compliance, discontinuation and switching of calcium channel blockers in 20,156 Chinese patients. Am J Hypertens 2009, (22):904–10.Google Scholar
  13. Wong MCS, Su XF, Jiang JY, Tang JL, Griffiths SM: Profiles of Discontinuation and Switching of Thiazide Diuretics: a Cohort Study among 9,398 Chinese Hypertensive Patients. Hypertension Research 2011, in press.Google Scholar
  14. Panjrath GS, Messerli FH: Beta blockers in hypertension. In Comprehensive Hypertension. Edited by: Lip GYH, Hall HE. Philadelphia: Mosby Elsevier; 2007:964.Google Scholar
  15. Burke TA, Sturkenboom MC, Lu S, Wenworth CE, Lin Y, Rhoads GG: Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006, 24: 1193–1200. 10.1097/01.hjh.0000226211.95936.f5PubMedView ArticleGoogle Scholar
  16. Mazzaglia G, Mantovani LG, Sturkenboom MCJM, Filippi A, Trifiro G, Cricelli C, Brignoli O, Caputi AP: Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005, 23: 2093–2100. 10.1097/01.hjh.0000186832.41125.8aPubMedView ArticleGoogle Scholar
  17. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire J-P: Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005, 19: 607–613. 10.1038/sj.jhh.1001873PubMedView ArticleGoogle Scholar
  18. Hoer A, Gothe H, Khan ZM, Schiffhorst G, Vincze G, Haussler B: Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. J Hum Hypertens 2007, 21: 744–746. 10.1038/sj.jhh.1002223PubMedView ArticleGoogle Scholar
  19. Inkster ME, Donnan PT, MacDonald TM, Sullivan FM, Fahey T: Adherence to antihypertensive medication and association with patient and practice factors. J Hum Hypertens 2006, 20: 295–297. 10.1038/sj.jhh.1001981PubMedView ArticleGoogle Scholar
  20. Brown MJ: Hypertension and ethnic group. BMJ 2006, 332: 833–836. 10.1136/bmj.332.7545.833PubMed CentralPubMedView ArticleGoogle Scholar
  21. Charmey B, Meyer BR, Frishman WH, et al.: Gender, race, and genetic issues in cardiovascular pharmacotherapeutics. In Cardiovascular Pharmacotherapeutics. Edited by: Frishman WH. New York: McGraw ill; 1997:1347–61.Google Scholar
  22. Hou HH, Koshakji RP, Silberstein DJ, et al.: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med 1989, 320: 565–70. 10.1056/NEJM198903023200905View ArticleGoogle Scholar
  23. Wong MCS, Jiang Y, Griffiths S: Factors associated with antihypertensive drug compliance in 83,884 Chinese patients: a cohort study. Journal of Epidemiology and Community Health 2010, 64: 895–901. 10.1136/jech.2009.091603PubMedView ArticleGoogle Scholar
  24. Cheung NT, Health informatics, Hospital Authority, Hong Kong: Realizing the benefits of eHealth in Hong Kong. [http://www.ehealth.org.hk/Speaker/Dr%20Ngai%20Tseung%20CHEUNG.pdf]
  25. Population by-census Hong Kong Special Administrative Region, China; 2006. [http://www.bycensus2006.gov.hk/data/data2/index.htm]
  26. Panjrath GS, Messerli FH: Beta blockers in hypertension. In Comprehensive Hypertension 2007 Edited by: Lip GYH, Hall JE. 2007, 959–970.View ArticleGoogle Scholar
  27. Colfer HT, Cottier C, Sanchez R, Julius S: Role of cardiac factors in the initial hypotensive action by beta-adrenoceptor blocking agents. Hypertension 1984, 6: 145–51.PubMedGoogle Scholar
  28. Messerli FH, Sundgaard-Riise K, Ventura HO, et al.: Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983, 2: 983–86.PubMedView ArticleGoogle Scholar
  29. Lund-Johansen P, Ormvik P: Hemodynamic patterns of untreated hypertensive disease. In Hypertension: Pathophysiology, Diagnosis, and Management. 2nd edition. Edited by: Laragh JH BB. New York: Raven Press; 1995:323–42.Google Scholar
  30. McNeely W, Goa KL: Nebivolol in the management of essential hypertension: A review. Drugs 1999, 57: 633–51. 10.2165/00003495-199957040-00011PubMedView ArticleGoogle Scholar
  31. Minneman KP, Hedberg A, Molinoff PB: Comparison of beta adrenergic receptor subtypes in mammalian tissues. J Pharmacol Exp Ther 1979, 211: 502–08.PubMedGoogle Scholar
  32. Opie LH SE, Frishman WH et al: Beta blocking agents. In Drugs for the Heart. 4th edition. Edited by: Opie LH, Frishman WH, et al. Philadelphia: W.B. Saunders; 1995:1–30.Google Scholar
  33. Messerli FH, Grossman E, Goldbourt U: Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279: 1903–07. 10.1001/jama.279.23.1903PubMedView ArticleGoogle Scholar
  34. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115: 41–46. 10.1016/S0002-9343(03)00158-XPubMedView ArticleGoogle Scholar
  35. Schulman SP, Weiss JL, Becker LC, et al.: The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990, 322: 1350–56. 10.1056/NEJM199005103221904PubMedView ArticleGoogle Scholar
  36. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101: 1653–59.PubMedView ArticleGoogle Scholar
  37. Grossman E, Messerli FH: Why beta blockers are not cardioprotective in elderly patients with hypertension. Curr Cardiol Rep 2002, 4: 468–73. 10.1007/s11886-002-0108-3PubMedView ArticleGoogle Scholar

Copyright

© Wong et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.